News

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.
The Trump administration has proposed cutting a $56 million grant that teaches first responders how to use the lifesaving ...
ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...
A new nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment ...
Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...
The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...
The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...
An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...
Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...
A drug derived from ketamine will be added to the PBS, helping tens of thousands of Australians struggling with depression to ...